Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
About 3% of all cancer patients suffer from carcinoma of unknown primary site (CUP). In spite of its rarity, we will encounter them. While CUPs manifest a wide variety of clinical presentations, they have often resulted in poor prognosis. Although platinum/taxane combination chemotherapy, e.g. carbo...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Karger Publishers
2014-08-01
|
| Seri Bilgileri: | Case Reports in Oncology |
| Konular: | |
| Online Erişim: | http://www.karger.com/Article/FullText/366268 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|